What Are Some Examples of Novel Prodrugs in Development?
Recent advancements have led to the development of several novel prodrugs with promising results in preclinical and clinical settings. A notable example is the use of antibody-drug conjugates (ADCs), which combine the targeting capabilities of monoclonal antibodies with the potent cytotoxic effects of chemotherapeutic agents. These prodrugs remain inactive until the antibody binds to a specific antigen on cancer cells, triggering the release of the cytotoxic agent.
